Education
About Us
Working with TipRanks
Follow Us
Zai Lab (ZLAB)
NASDAQ:ZLAB
Earnings Data
Report Date
May 13, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.54Last Year’s EPS
-0.55Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: 3.85%
|Next Earnings Date:May 13, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with strong revenue growth, successful product launches, and pipeline advancements. Despite some challenges, such as limited immediate impact from certain product launches and competitive pressures, the company is on track towards profitability and maintains a strong cash position.Company Guidance
During the call, Zai Lab provided detailed guidance on its performance and expectations. For 2025, the company anticipates total revenues to be between $560 million and $590 million, reflecting strong growth from products such as VYVGART, ZEJULA, and NUZYRA. The company reported a 66% increase in fourth-quarter revenue to $109.1 million and a 50% rise for the full year, totaling $399 million. VYVGART, which generated $93.6 million in 2024, is expected to drive significant growth, with new formulations and approvals anticipated to enhance its market penetration. Zai Lab aims to achieve profitability by the fourth quarter of 2025, driven by operational efficiencies that have already resulted in a 45% reduction in fourth-quarter operational loss and a 23% decrease for the full year. The company maintains a robust cash position of $879.7 million to support its growth strategy, including advancing its pipeline and launching new products.Record Revenue Growth
Total revenue for 2024 grew 50% year-on-year, with a 66% growth in the fourth quarter. Full-year revenue was $399 million.
Successful Launches and Product Performance
VYVGART generated $93.6 million in sales in its first year, with fourth quarter sales of $30 million. New products like VYVGART Hytrulo, AUGTYRO, and XACDURO were launched successfully.
Pipeline Advancements
Significant progress in the pipeline, including positive data readouts for KarXT, Tumor Treating Fields, and TIVDAK. Regulatory submissions and approvals are on track for multiple products.
Cost Efficiency and Profitability Outlook
Loss from operations improved by 45% in Q4 and 23% for the full year. The company is on track to reach profitability by Q4 2025.
Strong Cash Position
The company maintains a robust cash position of $879.7 million to support future growth.
---
ZLAB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ZLAB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $35.07 | $34.38 | -1.97% |
| Nov 12, 2024 | $31.09 | $28.96 | -6.85% |
| Aug 06, 2024 | $18.11 | $16.65 | -8.06% |
| May 08, 2024 | $16.57 | $21.01 | +26.80% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Zai Lab (ZLAB) report earnings?
Zai Lab (ZLAB) is schdueled to report earning on May 13, 2025, TBA Not Confirmed.
What is Zai Lab (ZLAB) earnings time?
Zai Lab (ZLAB) earnings time is at May 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ZLAB EPS forecast?
ZLAB EPS forecast for the fiscal quarter 2025 (Q1) is -0.54.
---